查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963864

全球黏合贴片市场－产业规模、份额、趋势、机会、预测：按产品类型、通路、地区和竞争格局划分，2021-2031年

Pain Patch Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球止痛贴市场预计将从 2025 年的 53.4 亿美元成长到 2031 年的 70.8 亿美元，复合年增长率为 4.81%。

该领域包括经皮给药系统，旨在透过皮肤将可控镇痛药物直接输送到血液中。一个关键的成长要素是人们越来越倾向于选择不涉及胃肠道的非侵入性给药方式。这最大限度地减少了通常与口服镇痛药相关的全身性副作用。此外，人口老化和文明病盛行率的上升，使得人们对便捷且可持续的疼痛管理解决方案的需求日益迫切。根据国际疼痛研究协会预测，到2024年，全球超过20%的人口将患有慢性疼痛，这意味着庞大的患者群体亟需有效且长期的治疗方案。

市场概览
预测期 2027-2031
市场规模：2025年 53.4亿美元
市场规模：2031年 70.8亿美元
复合年增长率：2026-2031年 4.81%
成长最快的细分市场 非阿片类贴剂
最大的市场 北美洲

儘管市场需求强劲，但由于经皮给药系统法规结构严格，市场仍面临许多障碍。製造商必须经过复杂的核准程序，证明黏合剂的安全性以及药物吸收的长期稳定性。这些严格的合规标准往往导致产品开发週期延长和成本增加，严重阻碍了市场快速成长和新配方的上市。

市场驱动因素

随着医疗机构优先考虑更安全的口服麻醉剂替代方案，向非鸦片类和非成瘾性疼痛治疗​​的转变正在加速，从根本上重塑了全球止痛贴市场。这项转变主要源自于持续不断的鸦片类药物滥用公共卫生危机，促使临床医生和监管机构实施以经皮治疗方法为重点的多面向疼痛管理策略。这些措施的成功在近期发布的国家数据中得到了印证。根据美国疾病管制与预防中心 (CDC) 于 2025 年 2 月发布的《药物过量死亡初步报告》，截至 2024 年 9 月的 12 个月的初步以金额为准显示，药物过量死亡人数下降了约 24%。这一显着下降凸显了整个产业向非全身性解决方案的转变。例如，双氯芬酸钠和Lidocaine贴片可在局部缓解疼痛，而不会像传统鸦片类药物那样带来呼吸抑制和成瘾等严重风险。

同时，经皮给药系统的技术进步正透过提高患者用药便利性和药物渗透性来推动市场扩张。控制释放膜和黏附技术的创新增强了药物的持续释放，直接促进了领先生产商的商业性成功。例如，久光製药株式会社在其2025年4月发布的「截至2025年2月的财年合併会计报告」中披露，其销售额同比增长10.1%，这主要归功于其旗舰经皮製剂的强劲表现。此外，监管机构也积极支持这些创新。根据《贝克尔医院评论》2025年12月报道，美国食品药品监督管理局（FDA）当年核准了73种首次学名药，其中包括一种用于治疗带状疱疹后遗症神经痛的新型Lidocaine贴剂，从而扩大了重要经皮疗法的可及性。

市场挑战

严格的经皮给药系统监管架构是全球止痛贴市场扩张的主要障碍。製造商必须遵守复杂的核准流程，以检验黏合剂成分的安全性并确保药物长期稳定吸收。这些严格的合规要求需要进行全面的临床试验和精细的配方改进，直接导致产品开发週期延长和营运成本增加。因此，这些高准入门槛限制了新产品的推出频率，并阻碍了潜在的市场进入者，从而减缓了整体市场成长。

繁重的监管负担造成了资金和时间上的双重压力，令许多公司难以承受。根据美国製药商协会（PhRMA）预测，到2024年，一种新药的平均研发週期将长达10至15年，需要约26亿美元的投资。如此庞大的资源需求凸显了将创新经皮镇痛方案推向商业化的复杂性，也有效阻碍了製药业快速回应患者日益增长的需求。

市场趋势

天然、草本和含CBD产品的日益普及正在显着影响市场格局。随着消费者越来越寻求替代传统药物的整体疗法，这一趋势推动了对含有樟脑、薄荷醇和麻提取物等植物来源镇痛成分的非处方经皮贴剂的需求。与合成鸦片类药物相比，这些产品被认为更安全，适合长期使用。消费者偏好的这种转变也体现在消费者对知名天然疗法的数位参与度不断提高。根据2024年3月发布的《久光製药美国公司：90年来在疼痛缓解领域的开拓》报告，该公司旗舰贴片品牌的搜寻量在2023年飙升了98.8%。这项数据凸显了大众对便捷易得、处方笺的天然贴片疗法在日常疼痛缓解方面的强烈需求。

同时，非药物疗法领域也在取得进展，智慧互联的可穿戴止痛贴片应运而生。这些先进系统利用生物电子学和奈米技术，透过皮肤调节疼痛讯号，为担心副作用和药物交互作用的患者提供无药物的替代方案。越来越多的同行评审研究支持这些创新技术的临床可行性。根据美国国立卫生研究院 (NIH) 于 2024 年 4 月发表的综述文章《奈米技术在疼痛管理中的应用》，使用新型奈米电容器贴片的患者术后疼痛较标准治疗降低了 34%。这种电子调节技术的整合标誌着疼痛缓解领域向个人化、数位化解决方案迈出了变革性的一步。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球黏合贴片市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（非鸦片类贴片、鸦片类贴片）
    • 依类型（处方药、非处方药）
    • 分销管道（医院药房、药局/零售药房、线上供应商）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美黏合补片市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲黏合贴片市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区黏合贴片市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲黏合贴片市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲黏合贴片市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球黏合贴片市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • NEXGEL Inc.
  • Viatris Inc.
  • Johnson and Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sorrento Therapeutics Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo, Inc.
  • Purdue Pharma LP
  • Amneal Pharmaceuticals LLC
  • GrUnenthal GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18840

The Global Pain Patch Market is projected to expand from a valuation of USD 5.34 billion in 2025 to USD 7.08 billion by 2031, reflecting a compound annual growth rate of 4.81%. This sector comprises transdermal therapeutic systems engineered to administer controlled analgesic medication directly into the bloodstream through the skin. Key growth factors include a growing preference for noninvasive delivery methods that avoid the gastrointestinal tract, thereby minimizing systemic side effects typically linked to oral painkillers. Furthermore, the rising geriatric population and the increasing incidence of lifestyle-related conditions create a strong need for convenient, sustained pain management options. According to the International Association for the Study of Pain, over 20% of the world's population suffered from chronic pain in 2024, highlighting the vast patient base requiring effective, long-term therapeutic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.34 Billion
Market Size 2031USD 7.08 Billion
CAGR 2026-20314.81%
Fastest Growing SegmentNon-Opioid Patches
Largest MarketNorth America

Despite strong demand, the market encounters substantial hurdles due to the strict regulatory frameworks overseeing transdermal drug delivery systems. Manufacturers face intricate approval procedures to prove the safety of adhesive materials and the consistent efficacy of drug absorption over time. These rigorous compliance standards frequently lead to prolonged product development cycles and elevated costs, acting as significant barriers to rapid market growth and the launch of new formulations.

Market Driver

The Global Pain Patch Market is being fundamentally reshaped by an accelerated transition toward non-opioid and non-addictive pain treatments, as healthcare providers prioritize safer alternatives to oral narcotics. This shift is largely propelled by the ongoing public health crisis regarding opioid abuse, prompting clinicians and regulatory bodies to implement multimodal pain management strategies that highlight transdermal options. The success of these measures is evident in recent national data; according to the Centers for Disease Control and Prevention's 'Provisional Drug Overdose Death Counts' report from February 2025, provisional figures indicated a nearly 24% decrease in drug overdose deaths for the 12-month period ending in September 2024. This notable decline emphasizes the industry-wide move toward non-systemic solutions, such as diclofenac and lidocaine patches, which provide localized relief without the severe risks of respiratory depression and dependency linked to traditional opioids.

Concurrently, technological progress in transdermal drug delivery systems is driving market expansion by improving patient convenience and drug permeation. Innovations in rate-controlling membranes and adhesive technologies have enhanced the sustained release of medication, directly bolstering the commercial success of major manufacturers. For example, Hisamitsu Pharmaceutical reported in its April 2025 'Consolidated Financial Results for the Fiscal Year Ended February 28, 2025' that net sales rose by 10.1% year-on-year, a growth attributed largely to the strong performance of its flagship transdermal products. Additionally, regulatory agencies are actively backing this innovation; according to Becker's Hospital Review in December 2025, the FDA approved 73 first-time generic drugs during the year, including a new lidocaine patch formulation for post-herpetic neuralgia, thereby widening access to critical transdermal therapies.

Market Challenge

The stringent regulatory frameworks that govern transdermal drug delivery systems represent a major obstacle to the expansion of the Global Pain Patch Market. Manufacturers are obligated to navigate intricate approval pathways to validate the safety of adhesive ingredients and guarantee consistent drug absorption efficacy over extended durations. These exacting compliance requirements demand comprehensive clinical trials and meticulous formulation refinements, which directly result in prolonged product development schedules and increased operational expenses. As a result, these high entry barriers restrict the frequency of new product introductions and discourage potential market entrants, thereby retarding overall market growth.

This heavy regulatory burden establishes a financial and temporal landscape that is challenging for many enterprises to maintain. According to the Pharmaceutical Research and Manufacturers of America, the average development timeline for a new pharmaceutical product in 2024 ranged from 10 to 15 years, requiring an investment of roughly $2.6 billion. This significant resource demand highlights the complexity of bringing innovative transdermal pain management solutions to the commercial stage, effectively hindering the industry's capacity to swiftly respond to rising patient needs.

Market Trends

The market is being significantly shaped by the increasing popularity of natural, herbal, and CBD-infused products, as consumers increasingly search for holistic alternatives to standard pharmaceuticals. This trend is fueling demand for over-the-counter transdermal systems containing plant-based analgesics such as camphor, menthol, and hemp extracts, which are viewed as safer for long-term application compared to synthetic opioids. This shift in consumer preference is reflected in the rising digital engagement with well-known natural formulations. According to the 'Hisamitsu America Marks 90 Years of Pioneering Pain Relief' report from March 2024, search interest for the company's primary patch brand surged by 98.8% in 2023. This data point underscores the strong public intention to use accessible, non-prescription natural patch therapies for daily pain relief.

At the same time, the sector is experiencing a non-pharmacological evolution with the advent of smart and connected wearable pain patches. These sophisticated systems utilize bio-electronics and nanotechnology to modulate pain signals through the skin, providing a drug-free alternative for patients concerned about side effects or chemical interactions. The clinical feasibility of these innovations is increasingly bolstered by peer-reviewed studies. According to an April 2024 review by the National Institutes of Health titled 'Nanotechnology for Pain Management,' patients using a novel nanocapacitor-based patch reported a 34% decrease in postoperative pain relative to the standard of care. This incorporation of electronic modulation signifies a transformative advance toward personalized, digital-first solutions for pain relief.

Key Market Players

  • NEXGEL Inc.
  • Viatris Inc.
  • Johnson and Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sorrento Therapeutics Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo, Inc.
  • Purdue Pharma L.P.
  • Amneal Pharmaceuticals LLC
  • GrUnenthal GmbH

Report Scope

In this report, the Global Pain Patch Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pain Patch Market, By Product Type

  • Non-Opioid Patches
  • Opioid Patches

Pain Patch Market, By Type

  • Prescription Medicines
  • OTC Medicines

Pain Patch Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

Pain Patch Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pain Patch Market.

Available Customizations:

Global Pain Patch Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pain Patch Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Non-Opioid Patches, Opioid Patches)
    • 5.2.2. By Type (Prescription Medicines, OTC Medicines)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pain Patch Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pain Patch Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Pain Patch Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Pain Patch Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Pain Patch Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pain Patch Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Pain Patch Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Pain Patch Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Pain Patch Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Pain Patch Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Pain Patch Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pain Patch Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Pain Patch Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Pain Patch Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Pain Patch Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Pain Patch Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Pain Patch Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pain Patch Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Pain Patch Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Pain Patch Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Pain Patch Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pain Patch Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Pain Patch Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Pain Patch Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pain Patch Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NEXGEL Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Viatris Inc.
  • 15.3. Johnson and Johnson
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Sorrento Therapeutics Inc.
  • 15.6. Hisamitsu Pharmaceutical Co., Inc.
  • 15.7. Endo, Inc.
  • 15.8. Purdue Pharma L.P.
  • 15.9. Amneal Pharmaceuticals LLC
  • 15.10. GrUnenthal GmbH

16. Strategic Recommendations

17. About Us & Disclaimer